New Treatments for Malignant Ventricular Arrhythmias Emerge from Cardiology & Oncology Integration

European Institute of Oncology shared a post on LinkedIn: “An important collaboration between Monzino Cardiology Center and European Institute of Oncology opens up new perspectives in the treatment of malignant ventricular arrhythmias. The results of STRA-MI-VT, the first Italian study on the use of stereotactic radiotherapy in a single session, show a control of arrhythmias greater than 80%, with better results than traditional techniques. A goal made possible by the joint work of Monzino cardiologists and IEO radio-oncologists, led respectively by Dr. Corrado Carbucicchio – Director of the Operational Unit for the treatment of Ventricular Arrhythmias Monzino, Creator and Principal Investigator of the Study – and by Prof. Barbara Jereczek-Fossa – Director of the IEO Radiotherapy Division, which confirms the value of the integration between cardiological and oncological skills. The STRA-MI-VT study, one of the most representative in the world for the methodology used and for the severity and complexity of the patients treated, paves the way for a new treatment strategy: it is reasonable to think that even patients with less dramatic arrhythmic presentations can benefit from this innovative therapeutic option in the short term.” Barbara Jereczek-Fossa, Director of the Radiotherapy Division at , shared this post, adding: “STAR (radioablation) was associated with a significant reduction in ICD therapies, with an average decrease of 81%. STRA-MI-VT phase I/II trial reflects true teamwork. Thank you to all Colleagues involved and to the Patients who made it possible.”